This session delves into the critical role of Intravascular Ultrasound (IVUS) in characterizing and managing calcified coronary lesions. Attendees can explore an imaging-guided approach to calcium treatment, including case presentations that demonstrate stent selection and procedural optimization. Emphasis is placed on applying imaging-based optimization metrics to...

This session addresses the challenges and strategies in optimizing guided-directed medical therapy for acute heart failure patients, especially those intolerant to up-titration. It also covers the assessment and timing for cardiac resynchronisation therapy (CRT), highlighting the benefits of combining medical therapy and device implantation to improve...

This comprehensive session reviews registries and clinical trials in mitral transcatheter edge-to-edge repair (TEER). It includes discussions on novel TEER systems, international consensus on PASCAL implants, anatomical predictors of procedural success, and long-term outcomes including ventricular and atrial remodeling after intervention, as well as emerging therapies...

This session examines the balance between ischemic and bleeding risks by comparing monotherapy regimens and dual antiplatelet therapy (DAPT) following PCI. Key topics include clopidogrel versus aspirin monotherapy, aspirin discontinuation timing after ACS, and the impact of P2Y12 adherence on clinical outcomes in high-risk and oral...

Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.